VERADIGM INC (MDRX)
(Delayed Data from OTC)
$9.26 USD
-0.05 (-0.54%)
Updated Oct 14, 2024 03:46 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
Price, Consensus and EPS Surprise
MDRX 9.26 -0.05(-0.54%)
Will MDRX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for MDRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MDRX
GE HealthCare Acquires Intelligent Ultrasound's Clinical AI Business
Veradigm (MDRX) to Acquire AI Service Provider ScienceIO
MDRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Veradigm (MDRX) & MedAllies Partner for Better Care Decisions
Veradigm's (MDRX) Acquires Koha Health to Solidify Market Presence
Braze, Inc. (BRZE) Reports Q3 Loss, Tops Revenue Estimates
Other News for MDRX
Veradigm says Veradigm eChart Courier expands to 300,000 healthcare providers
Veradigm Ranked Top Vendor by KLAS
Veradigm Ends Credit Agreement with JPMorgan Chase
Veradigm Named as the Top Vendor for End-to-End Revenue Cycle Management Solutions
Veradigm gains after report of bids in sales process